Follow
Zhili Zheng
Zhili Zheng
National Cancer Institute
Verified email at mail.nih.gov
Title
Cited by
Cited by
Year
Cancer regression in patients after transfer of genetically engineered lymphocytes
RA Morgan, ME Dudley, JR Wunderlich, MS Hughes, JC Yang, ...
Science 314 (5796), 126-129, 2006
41092006
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
RA Morgan, N Chinnasamy, D Abate-Daga, A Gros, PF Robbins, Z Zheng, ...
Journal of immunotherapy 36 (2), 133-151, 2013
12792013
T-cell transfer therapy targeting mutant KRAS in cancer
E Tran, PF Robbins, YC Lu, TD Prickett, JJ Gartner, L Jia, A Pasetto, ...
New England Journal of Medicine 375 (23), 2255-2262, 2016
12442016
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
N Zacharakis, H Chinnasamy, M Black, H Xu, YC Lu, Z Zheng, A Pasetto, ...
Nature medicine 24 (6), 724-730, 2018
7732018
Immunogenicity of somatic mutations in human gastrointestinal cancers
E Tran, M Ahmadzadeh, YC Lu, A Gros, S Turcotte, PF Robbins, ...
Science 350 (6266), 1387-1390, 2015
7482015
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability
CJ Cohen, Y Zhao, Z Zheng, SA Rosenberg, RA Morgan
Cancer research 66 (17), 8878-8886, 2006
5782006
Transformation by Wnt family proteins correlates with regulation of beta-catenin.
H Shimizu, MA Julius, M Giarre, Z Zheng, AM Brown, J Kitajewski
Cell growth & differentiation: the molecular biology journal of the American …, 1997
5631997
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions
PF Robbins, YF Li, M El-Gamil, Y Zhao, JA Wargo, Z Zheng, H Xu, ...
The Journal of Immunology 180 (9), 6116-6131, 2008
4132008
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
Y Zhao, QJ Wang, S Yang, JN Kochenderfer, Z Zheng, X Zhong, ...
The Journal of Immunology 183 (9), 5563-5574, 2009
4102009
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma
L Zhang, RA Morgan, JD Beane, Z Zheng, ME Dudley, SH Kassim, ...
Clinical cancer research 21 (10), 2278-2288, 2015
3772015
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation
Y Zhao, Z Zheng, CJ Cohen, L Gattinoni, DC Palmer, NP Restifo, ...
Molecular therapy 13 (1), 151-159, 2006
3572006
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma
RA Morgan, LA Johnson, JL Davis, Z Zheng, KD Woolard, EA Reap, ...
Human gene therapy 23 (10), 1043-1053, 2012
3432012
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment
L Zhang, SP Kerkar, Z Yu, Z Zheng, S Yang, NP Restifo, SA Rosenberg, ...
Molecular therapy 19 (4), 751-759, 2011
3142011
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of …
RA Morgan, ME Dudley, YYL Yu, Z Zheng, PF Robbins, MR Theoret, ...
The Journal of Immunology 171 (6), 3287-3295, 2003
3042003
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
MS Hughes, YYL Yu, ME Dudley, Z Zheng, PF Robbins, Y Li, ...
Human gene therapy 16 (4), 457-472, 2005
2932005
Pilot trial of adoptive transfer of chimeric antigen receptor–transduced T cells targeting EGFRvIII in patients with glioblastoma
SL Goff, RA Morgan, JC Yang, RM Sherry, PF Robbins, NP Restifo, ...
Journal of immunotherapy 42 (4), 126-135, 2019
2772019
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines
Y Zhao, Z Zheng, PF Robbins, HT Khong, SA Rosenberg, RA Morgan
The Journal of Immunology 174 (7), 4415-4423, 2005
2652005
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines
Y Zhao, AD Bennett, Z Zheng, QJ Wang, PF Robbins, LYL Yu, Y Li, ...
The Journal of Immunology 179 (9), 5845-5854, 2007
2632007
Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE-A3
YC Lu, LL Parker, T Lu, Z Zheng, MA Toomey, DE White, X Yao, YF Li, ...
Journal of Clinical Oncology 35 (29), 3322, 2017
2472017
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition
S Yang, CJ Cohen, PD Peng, Y Zhao, L Cassard, Z Yu, Z Zheng, S Jones, ...
Gene therapy 15 (21), 1411-1423, 2008
2222008
The system can't perform the operation now. Try again later.
Articles 1–20